The analgesic effect of two different extended-release meloxicam formulations for attenuation of hypersensitivity in rats (Rattus norvegicus) (2026)

Ge, Y., Alamaw, E. D., Jampachaisri, K. et al.

Abstract

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) frequently administered every 24 hours to control mild to moderate pain in rodents. Extended-release meloxicam offers a refinement of less frequent dosing and an extended therapeutic window compared with the standard daily-dosed meloxicam formulation. The aim of this study was to compare the analgesic efficacy of 2 different extended-release meloxicam formulations to a standard meloxicam formulation in a rat incisional pain model. Adult Long-Evans rats (n = 33) were randomly assigned into one of 4 treatment groups (n = 8-9 per group): (1) saline (0.9% NaCl, 5 mL/kg, SC, once); (2) meloxicam (Melox; 2 mg/kg, SC, every 24 hours); (3) meloxicam extended-release polymer (Melox-ER; 4 mg/kg, SC, once); or (4) meloxicam extended-release suspension (Melox-XR; 4 mg/kg, SC, once). Under isoflurane anesthesia, a 1-cm longitudinal skin incision was made on the plantar hind paw 5 minutes after drug administration. Mechanical and thermal hypersensitivity assessments were performed one day before surgery (−24 hour), 4 hours after surgery (4 hour), and 3 consecutive days following surgery (24, 48, and 72 hours). Mechanical (4-48 hours) and thermal (4-72 hours) hypersensitivity were observed in the saline group. Melox-ER did not attenuate mechanical or thermal hypersensitivity at any time point. Melox and Melox-XR attenuated mechanical hypersensitivity at the 48-hour time point. No abnormal clinical signs were noted, but injection site reactions were noted in the Melox, Melox-ER, and Melox-XR groups. Further research is needed to evaluate rat meloxicam analgesic dosages for incisional pain.